welcome to DuchenneXchange- a positively charged Duchenne muscular dystrophy community.
- join today!
- log in
2D Strain Evaluation: Children With Duchenne Muscular Dystrophy Versus Healthy Children
study id #: NCT02418338
condition: Duchenne Muscular Dystrophy
Compare systolic function of left ventricle (LV) and right ventricle (VD) by 2D strain evaluation in Duchenne muscular dystrophy children versus a control group.
intervention: speckle tracking (2D strain) echocardiography
mechanism of action: No pharmaceutical intervention
last updated: June 10, 2019
start date: January 2014
estimated completion: June 2017
phase of development: N/A
size / enrollment: 99
Among the new echocardiographic techniques, two dimensional Speckle Tracking Imaging or "2D Strain" allows a dynamic study of regionalized and global ventricular contraction. With software for the spatial and temporal processing of a standard 2D image, this technique measures the displacement of natural markers present on the myocardial wall.
Used in adult cardiology since 2000, it could be eligible to pediatric population because of many potential applications. In Duchenne muscular dystrophy, myocardial disease leads to death in the third decade. Early diagnosis and preventive therapy remain a challenge. No clinic, biologic or radiologic markers can predict myocardial disease before advanced and irreversible heart failure.
Recent animals and human studies suggest that 2D strain anomalies could predict left ventricular systolic dysfunction in Duchenne muscular dystrophy. If it is confirmed, 2D strain could be used as early marker of myocardial disease in routine patient follow-up and in future therapeutic studies.
Purpose : - To compare systolic function of left ventricle (LV) and right ventricle (RV) by 2D strain evaluation in Duchenne muscular dystrophy children versus a control group.
• To correlate 2D Strain variables to conventional LV and RV echo variables.
• To evaluate 2D strain feasibility in normal children and Duchenne muscular myopathy population
- global longitudinal LV 2D strain [ Time Frame: day 1 ]
• Duchenne's muscular dystrophy (group 1) followed in our institution's referral center of neuromuscular diseases, during regular annual echocardiography follow-up.
• Healthy children (group 2), addressed in pediatric cardiology
Sarepta Therapeutics Announces Recipients of Route 79, The Duchenne Scholarship ProgramCAMBRIDGE, Mass., Sept. 05, 2019 (GLOB...
Strength Training in Duchenne Muscular DystrophyDuchenne muscular dystrophy (DMD) is a d...
Catabasis Pharmaceuticals Presents Data Supporting MRI T2 as a Potential Marker of Clinical Outcome in Duchenne Musc...Catabasis Pharmaceuticals, Inc. (NASDAQ:...
Santhera to present novel data highlighting the clinical relevance of peak expiratory flow as predictor of disease p...Santhera Pharmaceuticals announces that ...
L-citrulline and Metformin in Duchenne’s Muscular DystrophyThe purpose of the study is to show that...
Systemic Gene Delivery Clinical Trial for Duchenne Muscular DystrophyThe proposed clinical trial is a single-...
Plus Epicatechin Duchenne Muscular Dystrophy in Non-ambulatory AdolescentsThis single center open-label pilot stud...
University of Minnesota Clinical Trials May Offer Hope for Local Boys With Duchenne Muscular DystrophyA rare genetic disease called Duchenne M...
Quantitative muscle ultrasound detects disease progression in Duchenne muscular dystrophyObjective:We assessed changes in quantit...